Purple Biotech(PPBT) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Purple Biotech | 20-F: Registration statement / Annual report / Transition report
SEC16:07 ET · Announcements
Purple Biotech | 6-K/A: Report of foreign private issuer (related to financial reporting)
SECMar 10 11:50 ET · Announcements
Purple Biotech Sees Cash Runway Into Mid-2026
TipRanksMar 10 09:06 ET
Purple Biotech 4Q Loss/Shr 26c >PPBT
Dow JonesMar 10 09:02 ET
Purple Biotech Reports Q4 EPS (26c) Vs. ($3.80) Last Year
TipRanksMar 10 09:00 ET
Express News | Purple Biotech Q4 EPADS $(0.26)
BenzingaMar 10 08:58 ET

Comments

Teddy123

Yesterday 20:59

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

$Purple Biotech (PPBT.US)$
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Teddy123

Mar 5 06:20

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

$Purple Biotech (PPBT.US)$
Can Purple Biotech's Newly Patented Cancer Drug Combination Tackle Treatment Resistance?

Jaguar8

Mar 5 06:01

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Wednesday, 5th March at 7:00 am
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer
REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-...

2

Teddy123

Feb 18 06:25

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

$Purple Biotech (PPBT.US)$
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity

Jaguar8

Feb 18 06:01

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...

2

PPBT Purple Biotech

Trade Overview

Capital Trend

News

Comments

Trending Stocks